MiMedx Group (MDXG) Competitors

$3.64 +0.03 (+0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$3.71 +0.07 (+1.92%)

As of 05:19 PM Eastern

MDXG vs. ESTA, AORT, INSP, PLSE, and NVCR

Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Establishment Labs (ESTA), Artivion (AORT), Inspire Medical Systems (INSP), Pulse Biosciences (PLSE), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.

How does MiMedx Group compare to Establishment Labs?

MiMedx Group (NASDAQ:MDXG) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

: MiMedx Group has a net margin of 7.88% compared to Establishment Labs' net margin of -24.19%. MiMedx Group's return on equity of 21.03% beat Establishment Labs' return on equity.
Company Net Margins Return on Equity Return on Assets
MiMedx Group 7.88% 21.03% 15.92%
Establishment Labs -24.19% -201.79% -15.03%
: In the previous week, MiMedx Group had 5 more articles in the media than Establishment Labs. MarketBeat recorded 19 mentions for MiMedx Group and 14 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.41 beat MiMedx Group's score of 0.15 indicating that Establishment Labs is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiMedx Group
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Establishment Labs
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 1.7% of MiMedx Group shares are held by company insiders. Comparatively, 10.0% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: MiMedx Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MiMedx Group $389.42M 1.39 $48.58M $0.20 18.20
Establishment Labs $211.08M 9.88 -$51.06M -$1.74 N/A
: MiMedx Group has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
: MiMedx Group currently has a consensus target price of $8.50, suggesting a potential upside of 133.52%. Establishment Labs has a consensus target price of $86.86, suggesting a potential upside of 22.35%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Establishment Labs.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.71
Establishment Labs
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Establishment Labs	-24.19%	-201.79%	-15.03%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Establishment Labs	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.39	$48.58M	$0.20	18.20
Establishment Labs	$211.08M	9.88	-$51.06M	-$1.74	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

MiMedx Group beats Establishment Labs on 12 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to Artivion?

Artivion (NYSE:AORT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

: MiMedx Group has a net margin of 7.88% compared to Artivion's net margin of 2.21%. MiMedx Group's return on equity of 21.03% beat Artivion's return on equity.
Company Net Margins Return on Equity Return on Assets
Artivion 2.21% 7.43% 3.53%
MiMedx Group 7.88% 21.03% 15.92%
: In the previous week, MiMedx Group had 16 more articles in the media than Artivion. MarketBeat recorded 19 mentions for MiMedx Group and 3 mentions for Artivion. Artivion's average media sentiment score of 0.61 beat MiMedx Group's score of 0.15 indicating that Artivion is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artivion
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
MiMedx Group
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 86.4% of Artivion shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 1.7% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: MiMedx Group has lower revenue, but higher earnings than Artivion. MiMedx Group is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Artivion $441.33M 3.95 $9.77M $0.20 179.72
MiMedx Group $389.42M 1.39 $48.58M $0.20 18.20
: Artivion has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
: Artivion presently has a consensus target price of $51.00, suggesting a potential upside of 41.89%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 133.52%. Given MiMedx Group's higher probable upside, analysts plainly believe MiMedx Group is more favorable than Artivion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artivion
0 Sell rating(s)
1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.88
MiMedx Group
1 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.71

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.21%	7.43%	3.53%
MiMedx Group	7.88%	21.03%	15.92%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	1 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	3.95	$9.77M	$0.20	179.72
MiMedx Group	$389.42M	1.39	$48.58M	$0.20	18.20

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Artivion beats MiMedx Group on 8 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to Inspire Medical Systems?

MiMedx Group (NASDAQ:MDXG) and Inspire Medical Systems (NYSE:INSP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

: MiMedx Group presently has a consensus target price of $8.50, suggesting a potential upside of 133.52%. Inspire Medical Systems has a consensus target price of $85.00, suggesting a potential upside of 76.21%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities analysts plainly believe MiMedx Group is more favorable than Inspire Medical Systems.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.71
Inspire Medical Systems
1 Sell rating(s)

15 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.15
: Inspire Medical Systems has a net margin of 15.95% compared to MiMedx Group's net margin of 7.88%. MiMedx Group's return on equity of 21.03% beat Inspire Medical Systems' return on equity.
Company Net Margins Return on Equity Return on Assets
MiMedx Group 7.88% 21.03% 15.92%
Inspire Medical Systems 15.95% 10.96% 9.32%
: In the previous week, Inspire Medical Systems had 11 more articles in the media than MiMedx Group. MarketBeat recorded 30 mentions for Inspire Medical Systems and 19 mentions for MiMedx Group. Inspire Medical Systems' average media sentiment score of 0.94 beat MiMedx Group's score of 0.15 indicating that Inspire Medical Systems is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiMedx Group
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inspire Medical Systems
14 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Inspire Medical Systems has higher revenue and earnings than MiMedx Group. Inspire Medical Systems is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MiMedx Group $389.42M 1.39 $48.58M $0.20 18.20
Inspire Medical Systems $911.98M 1.52 $145.42M $4.98 9.69
: MiMedx Group has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
: 79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inspire Medical Systems	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Inspire Medical Systems	15.95%	10.96%	9.32%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspire Medical Systems	14 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.39	$48.58M	$0.20	18.20
Inspire Medical Systems	$911.98M	1.52	$145.42M	$4.98	9.69

Summary

Inspire Medical Systems beats MiMedx Group on 9 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Pulse Biosciences?

MiMedx Group (NASDAQ:MDXG) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

: MiMedx Group has a net margin of 7.88% compared to Pulse Biosciences' net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Pulse Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
MiMedx Group 7.88% 21.03% 15.92%
Pulse Biosciences N/A -73.77% -63.98%
: MiMedx Group presently has a consensus target price of $8.50, suggesting a potential upside of 133.52%. Pulse Biosciences has a consensus target price of $30.00, suggesting a potential upside of 60.86%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities analysts plainly believe MiMedx Group is more favorable than Pulse Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.71
Pulse Biosciences
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: 79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by insiders. Comparatively, 74.6% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: MiMedx Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MiMedx Group $389.42M 1.39 $48.58M $0.20 18.20
Pulse Biosciences $350K 3,622.84 -$72.78M -$1.08 N/A
: In the previous week, MiMedx Group had 13 more articles in the media than Pulse Biosciences. MarketBeat recorded 19 mentions for MiMedx Group and 6 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.47 beat MiMedx Group's score of 0.15 indicating that Pulse Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiMedx Group
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: MiMedx Group has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Pulse Biosciences	N/A	-73.77%	-63.98%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.39	$48.58M	$0.20	18.20
Pulse Biosciences	$350K	3,622.84	-$72.78M	-$1.08	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiMedx Group beats Pulse Biosciences on 12 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to NovoCure?

NovoCure (NASDAQ:NVCR) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

: MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity.
Company Net Margins Return on Equity Return on Assets
NovoCure -25.66% -50.34% -15.22%
MiMedx Group 7.88% 21.03% 15.92%
: NovoCure currently has a consensus target price of $27.29, suggesting a potential upside of 71.82%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 133.52%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than NovoCure.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NovoCure
1 Sell rating(s)
3 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.38
MiMedx Group
1 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.71
: 84.6% of NovoCure shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 1.7% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: MiMedx Group has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NovoCure $674.41M 2.73 -$136.23M -$1.53 N/A
MiMedx Group $389.42M 1.39 $48.58M $0.20 18.20
: In the previous week, NovoCure had 8 more articles in the media than MiMedx Group. MarketBeat recorded 27 mentions for NovoCure and 19 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.15 beat NovoCure's score of 0.03 indicating that MiMedx Group is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NovoCure
4 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
MiMedx Group
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
: NovoCure has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.34%	-15.22%
MiMedx Group	7.88%	21.03%	15.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$674.41M	2.73	-$136.23M	-$1.53	N/A
MiMedx Group	$389.42M	1.39	$48.58M	$0.20	18.20

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	1 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiMedx Group beats NovoCure on 11 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$542.16M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	18.20	38.85	29.04	28.47
Price / Sales	1.39	155.53	476.61	60.94
Price / Cash	6.64	57.88	27.62	36.52
Price / Book	2.10	7.03	9.67	6.67
Net Income	$48.58M	$23.62M	$3.55B	$332.53M
7 Day Performance	7.06%	3.67%	1.70%	2.01%
1 Month Performance	-7.14%	7.16%	5.62%	9.20%
1 Year Performance	-45.02%	67.03%	34.42%	39.59%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	4.3569 of 5 stars	$3.64 +0.8%	$8.50 +133.5%	N/A	$542.16M	$389.42M	18.20	870	Earnings Report Analyst Downgrade
ESTA Establishment Labs	3.1528 of 5 stars	$65.16 -0.5%	$86.86 +33.3%	N/A	$1.91B	$211.08M	N/A	1,004	News Coverage Upcoming Earnings Insider Trade
AORT Artivion	4.0204 of 5 stars	$36.55 -1.3%	$51.00 +39.5%	N/A	$1.78B	$441.33M	183.36	1,800	Upcoming Earnings
INSP Inspire Medical Systems	4.687 of 5 stars	$55.10 +0.1%	$101.41 +84.0%	N/A	$1.58B	$911.98M	11.03	1,333	Trending News Earnings Report Analyst Forecast Gap Down
PLSE Pulse Biosciences	2.0706 of 5 stars	$22.11 -2.4%	$30.00 +35.7%	N/A	$1.50B	$350K	N/A	140	News Coverage Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. ESTA, AORT, INSP, PLSE, and NVCR

How does MiMedx Group compare to Establishment Labs?

Summary

How does MiMedx Group compare to Artivion?

Summary

How does MiMedx Group compare to Inspire Medical Systems?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Summary

How does MiMedx Group compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. ESTA, AORT, INSP, PLSE, and NVCR

How does MiMedx Group compare to Establishment Labs?

Summary

How does MiMedx Group compare to Artivion?

Summary

How does MiMedx Group compare to Inspire Medical Systems?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Summary

How does MiMedx Group compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools